RecruitingPhase 1

Safety and Tolerability of EO2002

Mexico32 participantsStarted 2022-08-30

Plain-language summary

The goal of this clinical study is to assess the safety of intracameral injection of EO2002 in subjects post-cataract surgery.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Age ≥ 18 years.
✓. Subject has uncomplicated history of cataract that has progressed to a level requiring standard cataract extraction with intraocular lens implant surgery.
✓. Decreased endothelial cell count

✕. Other corneal disease
✕. Macular disease that in the investigator and/or sponsor's opinion would limit the ability of the subject to demonstrate improvement in BCVA.
✕. Descemet membrane detachment.
✕. History of uveitis or other ocular inflammatory disease.
✕. History of incisional glaucoma surgery
✕. Prior incisional eye surgery within 3 months prior to study treatment or penetrating or endothelial keratoplasty.
✕. History of ocular neoplasm.
✕. ETDRS BCVA in the fellow eye is worse than 35 letters (Snellen equivalent of 20/200).

Safety and Tolerability of EO2002

Timeframe: 26 weeks

NCT IDNCT05587205

SponsorAsociación para Evitar la Ceguera en México

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-10-06

Yara Luna